EUCTR2014-001441-24-AT
Active, Not Recruiting
Phase 1
Short-term effect of SGLT 2-inhibitor dapagliflozin on postprandial glucose excursion and insulin sensitivity in type 1 diabetic patients.
Medical University Innsbruck0 sites12 target enrollmentAugust 4, 2014
Conditionseffects of Dapagliflozin on postprandial glucose excursion and fasting glucose homeostasisTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
DrugsForxiga
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- effects of Dapagliflozin on postprandial glucose excursion and fasting glucose homeostasis
- Sponsor
- Medical University Innsbruck
- Enrollment
- 12
- Status
- Active, Not Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\-Typ 1 Diabetes Mellitus (duration at least 5 years)
- •\-C\-Peptid \< 0\.2µg/l
- •\-aged 18 to 60 years
- •\-Body Mass Index 20 – 25 kg/m2
- •\-absence of clinically relevant ketonuria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 12
- •F.1\.3 Elderly (\>\=65 years) no
Exclusion Criteria
- •\-insufficient venous conditions on both forearms and cubita
- •\-renal or hepatic insuffiency (including presence of mikroalbuminuria and determination of albumin/creatinin\-ratio)
- •\-History of malignant disease
- •\-concomitant medicaion/ substances that may influence postprandial glucose excursion and/or fasting glucose\-homeostasis within 3 months prior to study entry
- •\-alcoholabuse and/or drugabuse, nikotinconsumption \> 5 cigarettes per day
- •\-brittle\-diabetes
- •\-history of severe hypoglycemia, defined as hypoglycemia the need for forein assistance independent of the effectively measured blood glucose concentration within 12 months prior to study entry
- •\-any medical/individual condition that may jeopardize patients safety while participating in the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
N/A
ong-term effects of dapagliflozin, a SGLT2 inhibitor, on glucose metabolism in patients with type 2 diabetes mellitustype 2 diabetes mellitusJPRN-UMIN000026042Kurume University School of Medicine300
Not Yet Recruiting
N/A
Effect of SGLT2 inhibitor, Dapagliflozin combined with or without metformin on body composition in patients with type 2 diabetestype 2 diabetes mellitusJPRN-UMIN000030446St. Marianna University School of Medicine54
Active, Not Recruiting
N/A
Impact of treatment with Dapagliflozin in type 1 diabetic patientsEUCTR2015-002963-40-ESDra Cristina Avendaño Sola
Completed
Phase 4
Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial InfarctionMyocardial InfarctionDiabete Type 2Glucose IntoleranceNCT05050500Qingdao Central Hospital143
Completed
Phase 2
Effect of the SGLT-2 inhibitor dapagliflozine on impaired awareness of hypoglycemia in type 1 diabetesDiabetesImpaired Awareness of Hypoglycemiahypoglycemia unawareness10018424NL-OMON48616Radboud Universitair Medisch Centrum15